Acetyldigitoxin

• 产品号: DB00511
• CAS号: 25395-32-8
• 分子式: C43H66O14
• 分子量: 806.97574

产品别名

• 标题: Acetyldigitoxin
• IUPAC标准名: (2R,3R,4S,6S)-3-hydroxy-6-{[(2R,4S,6S)-4-hydroxy-6-{[(2R,3S,4S,6R)-4-hydroxy-6-{[(1S,2S,7R,10R,11S,14R,15R)-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-4-yl acetate
• IUPAC传统名: digitoxin, monoacetate
• 商标名: Acigoxin; Crystodigin; Acylanid

产品登记号

• CAS号: 25395-32-8

产品性质

• 疏水性(logP): 3.7
• 溶解度: 0.0274 mg/L at 25 oC [MEYLAN,WM et al. (1996)]

产品详细信息

详细说明 (English)

• Drug Groups: approved
• Description: Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
• Indication: Used for fast digitalization in congestive heart failure.
• Pharmacology: The main pharmacological effects of acetyldigitoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects. Its main cardiac effects are 1) a decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter, and 2) an increase of force of contraction via inhibition of the Na^+/K^+ ATPase pump.
• Toxicity: Toxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD50 = 7.8 mg/kg (orally in mice).
• Affected Organisms: Humans and other mammals
• Absorption: Bioavailability is 60 to 80% following oral administration.
• External Links: Wikipedia